GFI Publishes Clinical Study on Dietary Supplement (Cresko) for Asthenic Children: Psychosocial and Emotional Benefits The early years of life represent a critical phase in the overall development of children, profoundly influencing their future physical, social, cognitive, and emotional outcomes. Interventions adopted during this period, between 3 and 10 years old, offer significant benefits compared…
Success at Expomed Eurasia: Strengthening Connections and Showcasing Innovations From April 25th to 27th, we participated in Expomed Eurasia at the Tuyap Convention Center. Our presence in Hall 5, stand 521A-1, was an intense and rewarding experience. The fair provided us with an ideal platform to strengthen existing ties with our customers and to forge…
From a scientific perspective, Clinical Trials refer to the systematic study method conducted on humans (patients or healthy volunteers) with the purpose of verifying the effects of a product and/or identifying any adverse reactions, studying its absorption, distribution, metabolism, and excretion to establish its efficacy and tolerability. Clinical Trials must therefore confirm or refute the…
Gruppo FarmaImpresa at CPHI Barcelona 2023: Hall 2 – Booth #2U68 We are excited to share some exciting news with you! We will be participating in CPHI Barcelona 2023, one of the leading events in the pharmaceutical industry, taking place from October 24th to 26th at Fira Barcelona, Pavilion 2, Booth 2U68. This international forum…
EUDAMED: Gruppo FarmaImpresa achieves registration as a Manufacturer and Producer of Procedural Systems/Kits In recent years, the European Union has shown a growing concern for the safety and effectiveness of medical devices used within the European market. To enhance monitoring and ensure stricter control of these devices, the European Commission has developed EUDAMED (European Database…
B2B event: partnerships and opportunities in the Balkan market at the Metropol Palace in Belgrade We are thrilled to share the incredible B2B event that took place on June 26th and 27th, 2023, at the Metropol Palace in Belgrade! Thanks to the collaboration of the ITA – Italian Trade Agency, the Italian Embassy in Belgrade, and…
Gruppo FarmaImpresa obtains MDR Certification for intra-articular Syringes based on Hyaluronic Acid Gruppo FarmaImpresa has recently obtained the prestigious MDR (Medical Device Regulation) certification for high molecular weight hyaluronic acid-based intra-articular syringes, adding an important milestone to their portfolio of MDR-compliant CE certifications. The new Regulation (EU) 2017/745, known as MDR, represents the European regulatory…
Clinical study: Vaginal ovules containing hyaluronic acid, polycarbophil and lactic acid for vulvovaginal symptoms such as burning, dryness, irritation, dysuria and dyspareunia Gruppo FarmaImpresa is required, for regulatory reasons, to regularly follow a postmarketing surveillance system called postmarketing clinical follow-up (PMCF). The PMCF is a continuous and proactive process that aims to continuously evaluate the…
Gruppo FarmaImpresa: Event presentation at the Rome Congress Center for Health and Pharmaceutical Innovation in Serbia Gruppo FarmaImpresa, a leading pharmaceutical company, recently organized a very successful corporate event in collaboration with a major Serbian client operating in the Balkan countries. The event was held at the Cavour Congress Center, located in the picturesque setting…
Gruppo Farmaimpresa gets legality rating: guarantee of reliability and compliance Gruppo Farmaimpresa has, recently, reached an important milestone, obtaining the legality rating certificate issued by the Competition and Market Authority. But what is the legality rating and why is it important for a company? The legality rating is a certificate issued by the competent authorities…